(NASDAQ: AGIO) Agios Pharmaceuticals's forecast annual revenue growth rate of 67.95% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Agios Pharmaceuticals's revenue in 2025 is $40,875,000.On average, 4 Wall Street analysts forecast AGIO's revenue for 2025 to be $2,451,128,740, with the lowest AGIO revenue forecast at $2,337,424,069, and the highest AGIO revenue forecast at $2,608,758,158. On average, 4 Wall Street analysts forecast AGIO's revenue for 2026 to be $5,332,266,814, with the lowest AGIO revenue forecast at $4,449,414,248, and the highest AGIO revenue forecast at $5,903,114,229.
In 2027, AGIO is forecast to generate $11,858,636,027 in revenue, with the lowest revenue forecast at $9,257,314,863 and the highest revenue forecast at $13,775,869,918.